Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2024-10-22 Major Shareholding Noti…
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서(최대주주변경시)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report on Changes in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samjin Pharmaceutical. It details specific changes in share ownership, including the names of individuals, dates of transactions, and the number of shares involved. This type of filing is a regulatory requirement for disclosing significant changes in ownership structure and major shareholding status, which falls under the 'Major Shareholding Notification' category.
2024-10-22 Korean
최대주주변경
Major Shareholding Notification Classification · 1% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding a change in the company's largest shareholder (최대주주변경). It details the shift in ownership from 'Hana Pharm Co., Ltd. et al.' to 'Cho Eui-hwan et al.' due to stock sales. This type of disclosure regarding significant changes in shareholding structure and control falls under the category of Major Shareholding Notification (MRQ) as it reports a change in the identity of the largest shareholder.
2024-10-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the acquisition of shares by an executive (Jeon Sang-jin) of Samjin Pharmaceutical. This type of filing is a standard disclosure for insider trading/director dealings, which corresponds to the 'Director's Dealing' (DIRS) category.
2024-10-16 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 1% confidence The document is a 'Report on Acquisition Status by Trust Agreement' (신탁계약등에의한취득상황보고서) filed by Samjin Pharmaceutical. It details the company's purchase of its own shares through a trust contract with Mirae Asset Securities. This type of filing, which reports the company's buyback activity, is classified as 'Transaction in Own Shares' (POS) in our taxonomy.
2024-09-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required under the Capital Markets Act when an individual or entity acquires a significant stake (typically 5% or more) in a publicly traded company. It details the shareholding status, changes in ownership, and contractual agreements (such as stock collateralization). In the context of the provided categories, this falls under 'Major Shareholding Notification'.
2024-08-23 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for Samjin Pharmaceutical Co., Ltd., covering the period from January 1, 2024, to June 30, 2024. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.